Moderna Stock Falls
Moderna Stock Falls on Vaccine Revenue Concerns
Shares of Moderna Inc. (NASDAQ: MRNA) are down 3.2% in premarket trading after a bear note from Goldman Sachs. The firm lowered its rating on MRNA to "neutral" from "buy," and nearly halved its price target from $99 to $51, citing ongoing vaccine revenue challenges.
Moderna Inc (NASDAQ:MRNA) shares are trading lower Wednesday after Goldman Sachs downgraded the stock. Here's what you need ...
In a report released today, Tyler Van Buren from TD Cowen maintained a Hold rating on Moderna (MRNA – Research Report), with a price target of ...
10don MSN
While the headline numbers don't inspire much confidence, Moderna is a stock that deserves a closer look. The company still ...
The Centers for Disease Control and Prevention abruptly ordered its staff to cease all collaboration with the World Health ...
In 2023, Moderna initiated a study on a “pandemic influenza vaccine” to protect against H5 and H7 avian influenza viruses.
At the healthcare conference, Moderna lowered expected 2025 revenue to the range of $1.5 billion to $2.5 billion -- down from ...
Moderna and Novo Nordisk are once again in the bad books of the U.K.’s drug marketing watchdog. | Moderna and Novo Nordisk ...
The US Department of Health and Human Services awarded Moderna $590 million to continue developing a vaccine to protect against bird flu.
Vaccine manufacturer Moderna has welcomed the Chancellor's announcements regarding major infrastructure schemes.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback